132 related articles for article (PubMed ID: 32956454)
1. HRI depletion cooperates with pharmacologic inducers to elevate fetal hemoglobin and reduce sickle cell formation.
Peslak SA; Khandros E; Huang P; Lan X; Geronimo CL; Grevet JD; Abdulmalik O; Zhang Z; Giardine BM; Keller CA; Shi J; Hardison RC; Blobel GA
Blood Adv; 2020 Sep; 4(18):4560-4572. PubMed ID: 32956454
[TBL] [Abstract][Full Text] [Related]
2. Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells.
Grevet JD; Lan X; Hamagami N; Edwards CR; Sankaranarayanan L; Ji X; Bhardwaj SK; Face CJ; Posocco DF; Abdulmalik O; Keller CA; Giardine B; Sidoli S; Garcia BA; Chou ST; Liebhaber SA; Hardison RC; Shi J; Blobel GA
Science; 2018 Jul; 361(6399):285-290. PubMed ID: 30026227
[TBL] [Abstract][Full Text] [Related]
3. The proinflammatory cytokine GM-CSF downregulates fetal hemoglobin expression by attenuating the cAMP-dependent pathway in sickle cell disease.
Ikuta T; Adekile AD; Gutsaeva DR; Parkerson JB; Yerigenahally SD; Clair B; Kutlar A; Odo N; Head CA
Blood Cells Mol Dis; 2011 Dec; 47(4):235-42. PubMed ID: 21945571
[TBL] [Abstract][Full Text] [Related]
4. Computational identification of potential modulators of heme-regulated inhibitor (HRI) for pharmacological intervention against sickle cell disease.
Owoloye AJ; Olubode SO; Ogunleye A; Idowu ET; Oyebola KM
Res Sq; 2023 Dec; ():. PubMed ID: 38168168
[TBL] [Abstract][Full Text] [Related]
5. New Synthetic Isoxazole Derivatives Acting as Potent Inducers of Fetal Hemoglobin in Erythroid Precursor Cells Isolated from β-Thalassemic Patients.
Zuccato C; Cosenza LC; Tupini C; Finotti A; Sacchetti G; Simoni D; Gambari R; Lampronti I
Molecules; 2023 Dec; 29(1):. PubMed ID: 38202591
[TBL] [Abstract][Full Text] [Related]
6. Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease.
Lai ZS; Yeh TK; Chou YC; Hsu T; Lu CT; Kung FC; Hsieh MY; Lin CH; Chen CT; James Shen CK; Jiaang WT
Eur J Med Chem; 2021 Jan; 209():112938. PubMed ID: 33109398
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and pharmacological evaluation of pomalidomide derivatives useful for sickle cell disease treatment.
de Melo TRF; Dulmovits BM; Fernandes GFDS; de Souza CM; Lanaro C; He M; Al Abed Y; Chung MC; Blanc L; Costa FF; Dos Santos JL
Bioorg Chem; 2021 Sep; 114():105077. PubMed ID: 34130111
[TBL] [Abstract][Full Text] [Related]
8. Genetic reversal of the globin switch concurrently modulates both fetal and sickle hemoglobin and reduces red cell sickling.
De Souza DC; Hebert N; Esrick EB; Ciuculescu MF; Archer NM; Armant M; Audureau É; Brendel C; Di Caprio G; Galactéros F; Liu D; McCabe A; Morris E; Schonbrun E; Williams D; Wood DK; Williams DA; Bartolucci P; Higgins JM
Nat Commun; 2023 Sep; 14(1):5850. PubMed ID: 37730674
[TBL] [Abstract][Full Text] [Related]
9. Computational identification of potential modulators of heme-regulated inhibitor (HRI) for pharmacological intervention against sickle cell disease.
Owoloye AJ; Olubode SO; Ogunleye A; Idowu ET; Oyebola KM
J Biomol Struct Dyn; 2024 Mar; ():1-13. PubMed ID: 38555858
[TBL] [Abstract][Full Text] [Related]
10. Salubrinal induces fetal hemoglobin expression via the stress-signaling pathway in human sickle erythroid progenitors and sickle cell disease mice.
Lopez NH; Li B; Palani C; Siddaramappa U; Takezaki M; Xu H; Zhi W; Pace BS
PLoS One; 2022; 17(5):e0261799. PubMed ID: 35639781
[TBL] [Abstract][Full Text] [Related]
11. Quantitative Model-Based Assessment of Multiple Sickle Cell Disease Therapeutic Approaches Alone and in Combination.
Moody AT; Narula J; Maurer TS
Clin Pharmacol Ther; 2024 May; 115(5):1114-1121. PubMed ID: 38229405
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders.
Fard AD; Hosseini SA; Shahjahani M; Salari F; Jaseb K
Int J Hematol Oncol Stem Cell Res; 2013; 7(3):47-54. PubMed ID: 24505535
[TBL] [Abstract][Full Text] [Related]
13. rs11886868 and rs4671393 of BCL11A associated with HbF level variation and modulate clinical events among sickle cell anemia patients.
Chaouch L; Moumni I; Ouragini H; Darragi I; Kalai M; Chaouachi D; Boudrigua I; Hafsia R; Abbes S
Hematology; 2016 Mar; ():1-5. PubMed ID: 26125973
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Evaluation of a Novel Lentiviral Vector Driving Lineage-Specific BCL11A Knockdown for Sickle Cell Gene Therapy.
Brendel C; Negre O; Rothe M; Guda S; Parsons G; Harris C; McGuinness M; Abriss D; Tsytsykova A; Klatt D; Bentler M; Pellin D; Christiansen L; Schambach A; Manis J; Trebeden-Negre H; Bonner M; Esrick E; Veres G; Armant M; Williams DA
Mol Ther Methods Clin Dev; 2020 Jun; 17():589-600. PubMed ID: 32300607
[TBL] [Abstract][Full Text] [Related]
15. Large-Scale Drug Screen Identifies FDA-Approved Drugs for Repurposing in Sickle-Cell Disease.
Cannon M; Phillips H; Smith S; Williams K; Brinton L; Gregory C; Landes K; Desai P; Byrd J; Lapalombella R
J Clin Med; 2020 Jul; 9(7):. PubMed ID: 32708954
[TBL] [Abstract][Full Text] [Related]
16. Fetal-haemoglobin enhancing genotype at
Adeyemo TA; Ojewunmi OO; Oyetunji IA; Kalejaiye OO; Menzel S
EJHaem; 2021 Aug; 2(3):459-461. PubMed ID: 35844678
[TBL] [Abstract][Full Text] [Related]
17. Genomics of fetal haemoglobin: a targeted approach for reticulocyte transcriptome study.
Nkya S; Kaywanga F; Nzunda C; Karim S; Solomon D; Saukiwa E; Christopher H; Ngowi D; Johansen J; Urio F; Mgaya J; Chamba C; Hashim F; Ambroise E; Acquah SO; Makani J
Res Sq; 2023 Jun; ():. PubMed ID: 37461456
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic and kinetic insights into transcription factor biology via acute protein depletion.
Mehta S; Buyanbat A; Kai Y; Orkin SH
Exp Hematol; 2024 Jun; ():104250. PubMed ID: 38862078
[TBL] [Abstract][Full Text] [Related]
19. HbF Levels in Sickle Cell Disease Are Associated with Proportion of Circulating Hematopoietic Stem and Progenitor Cells and CC-Chemokines.
Minniti CP; Tolu SS; Wang K; Yan Z; Robert K; Zhang S; Crouch AS; Uehlinger J; Manwani D; Bouhassira EE
Cells; 2020 Sep; 9(10):. PubMed ID: 33003401
[TBL] [Abstract][Full Text] [Related]
20. ZNF410 Uniquely Activates the NuRD Component CHD4 to Silence Fetal Hemoglobin Expression.
Lan X; Ren R; Feng R; Ly LC; Lan Y; Zhang Z; Aboreden N; Qin K; Horton JR; Grevet JD; Mayuranathan T; Abdulmalik O; Keller CA; Giardine B; Hardison RC; Crossley M; Weiss MJ; Cheng X; Shi J; Blobel GA
Mol Cell; 2021 Jan; 81(2):239-254.e8. PubMed ID: 33301730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
